pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$VXRTVaxart, Inc.

$VXRT0.56000.00%
South San Francisco, CA, USupdated 14m ago

Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc.

SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
5
marketed
0
phase 3
0
catalysts ytd
3
approvals ytd
0
recalls ytd
0

Pipeline(5)

pipeline depth5 products
Preclinical: 1Phase 1: 1Phase 2: 3
1Preclinical1Phase 13Phase 2
Phase 2
COVID-19 (S Protein)
Coronavirus Disease 2019 (COVID-19)
Phase 2
Norovirus [strains Norwalk GI.1 + Sydney GII.4] (bivalent) vaccine
Norovirus Infections
Phase 2
VXAG-1.1NN
Norovirus Infections
Phase 1
norovirus [strain GI.1] vaccine
Norovirus Infections
Preclinical
VXAHPV-16.1
Human Papillomavirus (HPV) Associated Cancer

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Aug 6, 2026
earnings
$VXRT0.56000.00%
8d ago
Vaxart, Inc. earnings
Vaxart, Inc.
→
view all catalysts →

Insider activity

source: SEC Form 4
routine RSU / option mechanics (6)
  • Mar 28, 26tax coverTucker Sean · SVP, Chief Scientific Officer3,924 sh
  • Mar 28, 26tax coverCummings James F. · Chief Medical Officer3,292 sh
  • Mar 24, 26tax coverLo Steven · President, Chief Exec Officer126,028 sh
  • Mar 24, 26tax coverBerg Edward B · SVP, General Counsel36,418 sh
  • Mar 24, 26tax coverTucker Sean · SVP, Chief Scientific Officer36,418 sh
  • Mar 24, 26tax coverCummings James F. · Chief Medical Officer30,551 sh
🐶 Hiring Signal
No open roles indexed yet — view Vaxart, Inc. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$VXRT
SEC CIK
0000072444
country
US
source
sec_tickers
top tags
Infectious Disease4Oncology1Women's Health1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 14m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?